Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
danazol + recombinant human thrombopoietin
- Development stage
- Phase 3
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
A combination therapy consisting of danazol and recombinant human thrombopoietin (rhTPO) used for treating refractory immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA). Danazol is a synthetic steroid that alters erythrocyte membranes to resist osmotic lysis and protects platelets against complement-mediated lysis. Recombinant human thrombopoietin activates the thrombopoietin receptor (c-MPL) to promote megakaryocyte development and platelet production. The combination may provide synergistic effects in patients who are refractory to conventional therapies.
- Other names
- danazol + rhTPOdanazol + rHuTPO
02
Targets
SHBG (Sex hormone-binding globulin)TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on danazol + recombinant human thrombopoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on danazol + recombinant human thrombopoietin.